Abstract:OBJECTIVE Glucocorticoid (GC) has occupied a central role in the treatment of acute lymphoblastic leukemia due to its ability to induce apoptosis in neoplastic lymphoid cells. Glucocorticoid resistance is present among 20% initial acute lymphoblastic leukemia, even 80% refractory acute lymphoblastic leukemia. Glucocorticoid resistance has been an important determinant of clinical outcome. Glucocorticoid depends on glucocorticoid receptor (GR) to induce apoptosis. Glucocorticoid receptor, a number of nuclear hormone receptor superfamily, is mediated by many signal transduction systems. The mitogen-activated protein kinases (MAPK) superfamily of serine/threonine kinases has emerged as an important component of cellular signal transduction. Four MAP kinase families, ERK, p38 MAP kinase, JNK, and ERK5, have been well characterized. p38 MAPK usually plays a role in regulating apoptosis, cell cycle arrest and cytokines production, et al. In steroid resistance patients, IL-2 combined with IL-4 can decrease glucocorticoid receptor ligand-binding affinity via p38MAPK. In human alveolar epithelial A549 cells, dexamethasone could inhibit the activation of p38MAPK. It is unclear that the effect of p38MAPK on glucocorticoid receptor function induced by dexamethasone in CEM cells. This study aimed to investigate effect of p38 mitogen-activated protein kinase on glucocorticoid receptor function induced by dexamethasone in CEM cells. METHODS Cell viability was determined by trypan blue dye exclusion. Apoptosis was evaluated by morphology and flow cytometry. Glucocorticoid receptor protein and p-p38MAPK protein were analyzed by Western Blot. RESULTS When treatment with SB203580 and dexamethasone for 24 h to 72 h, the survival percentage was increased from 62.3%, 35.5% and 11.6% to 82.8%, 54.7% and 48.1%, respectively (P < 0.01). Co-treatment with SB203580 and dexamethasone resulted in the decrease of apoptotic percentage from 26.2% to 7.1% for 36 h (P < 0.01). p38 MAPK activation was apparent at 15 min, peaked at 1 h after dexamethasone treatment, and was sustained for 6 h. The phosphorylation was still observed at 48 h. Treatment with dexamethasone at 5 micromol/L for 12, 24, 36 and 48 h resulted in increase of GR(alpha) protein to 117%, 121%, 122% and 125% respectively. Unbinding to dexamethasone, GR(alpha) is in the cytoplasm. Nuclear-to-cytoplasmic ratio of GR(alpha) is 0.27. Treatment with dexamethasone at the same concentration and time resulted in the nuclear-to-cytoplasmic ratio increase to 0.48, 0.59, 0.95, 2.16 and 4.08 respectively. Combined treatment with SB203580 and dexamethasone resulted in the nuclear-to-cytoplasmic ratio decrease from 4.08 to 0.43 for 48 h (P < 0.05). The total GR(alpha) protein was unaffected. CONCLUSIONS Expression of GR(alpha) protein is upregulated and translocated into nucleus. p38MAPK enhances GR(alpha) protein translocation into nucleus.

[Effects of glucocorticoids on the proliferation of CD19 CAR-T cells targeting B-cell tumor cell lines]

[Effect of Prednisolon, Vincristine and Mitoxantrone on Glucocorticoid Receptor in HL-60 Cell Line].

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma

Dexamethasone inhibits the proliferation of tumor cells

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy

Comparison of the relative effects of five glucocorticoids on malignant cells of lymphatic system in vitro

Impact of Tocilizumab on Anti-Cd19 Chimeric Antigen Receptor T-cell Therapy in B-cell Acute Lymphoblastic Leukemia

Dexamethasone Enhances Programmed Cell Death 1 (PD-1) Expression During T Cell Activation: an Insight into the Optimum Application of Glucocorticoids in Anti-Cancer Therapy

Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy

An in Vitro and in Vivo Study of the Effect of Dexamethasone on Immunoinhibitory Function of Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells.

[P38 Mitogen-Activated Protein Kinase Mediates Glucocorticoid Receptor Function Induced by Dexamethasone in Acute Lymphoblastic Leukemia Cells].

[Effect of PD-1 Inhibitor Nivolumab on the Proliferation and Cytotoxicity of Anti-Cd19 Chimeric Antigen Receptor T Cells].

The Impact of Glucocorticoid on Proliferation and Differentiation of Bone Marrow Mesenchymal Stem Cells by Regulating DKK1

Dexamethasone Suppresses DU145 Cell Proliferation and Cell Cycle Through Inhibition of the Extracellular Signal-Regulated Kinase 1/2 Pathway and Cyclin D1 Expression

The effect of two glucan carboxymethyl derivatives with various substitution degrees on cyclophosphamide immunosuppression in mice

Androgen receptor reverts dexamethasone‑induced inhibition of prostate cancer cell proliferation and migration.

Glucocorticoid-Mediated Inhibition of Chemotherapy in Ovarian Carcinomas

Glucocorticoids Affect Human Dendritic Cell Differentiation and Maturation

Corticosteroids Induce Chemotherapy Resistance in the Majority of Tumour Cells from Bone, Brain, Breast, Cervix, Melanoma and Neuroblastoma.

A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host disease after allogeneic lymphocyte transplantation.

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome